Promising combo for Hard-to-Treat cancers hits early snag
NCT ID NCT05082025
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study was stopped early. The goal was to see if the combination was safe and effective, but the small size and early termination mean we cannot draw firm conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copanlisib (a PI3K inhibitor) and fulvestrant (a hormone therapy)
What this could lead to
If successful, this combination could offer a new treatment option for certain advanced hormone receptor-positive cancers that have specific genetic changes.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited and may not apply to larger populations. The combination may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.